stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Return on equity
Replimune Group, Inc.'s return on equity over the twelve months to 30 September 2026 was −115.8%, down 7.9 percentage points from fiscal 2026 (−107.9%). Over the past ten years it has ranged from −107.9% (fiscal 2026) to 99.6% (fiscal 2018) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −50.3% and below the Healthcare sector median of −25.6%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | −107.9% | (45.30) |
| FY2025 | −62.6% | (16.16) |
| FY2024 | −46.4% | (10.36) |
| FY2023 | −36.1% | (10.12) |
| FY2022 | −25.9% | (2.24) |
| FY2021 | −23.7% | 9.03 |
| FY2020 | −32.7% | 23.44 |
| FY2019 | −56.2% | (155.72) |
| FY2018 | 99.6% | 60.62 |
| FY2017 | 38.9% | — |
Against its own ten years
Low −107.9%
High 99.6%
Ten-year median
−34.4%
Current reading's percentile
10
Return on equity against peers
| Company | Return on equity |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ZYME Zymeworks Inc. compare | 15.0% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. compare | −21.8% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| IMNM Immunome, Inc. compare | −78.7% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| REPL Replimune Group, Inc. | −115.8% |
| Biotechnology industry median | −50.3% |
| Healthcare sector median | −25.6% |
| Market median | 1.95% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)